Search results for "immunotherapy"

showing 10 items of 830 documents

The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis

2017

Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-…

Allergen immunotherapymedicine.medical_specialtybusiness.industryCochrane Librarymedicine.diseasemedicine.disease_causelaw.invention03 medical and health sciences0302 clinical medicineAllergenPharmacotherapy030228 respiratory systemOtorhinolaryngologyRandomized controlled triallawMeta-analysisInternal medicinemedicineImmunology and AllergyObservational study030212 general & internal medicinebusinessAsthmaInternational Forum of Allergy & Rhinology
researchProduct

SLIT's Prevention of the Allergic March.

2018

PURPOSE OF REVIEW: The progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age. RECENT FINDINGS: Several studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondary prevention of allergic disease. The purpose of this manuscript is to r…

Allergic march0301 basic medicinePulmonary and Respiratory MedicineAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyDiseaseSublingual administration03 medical and health sciences0302 clinical medicineAllergen immunotherapy; Allergic march; Primary prevention; Secondary prevention; Sublingual immunotherapy; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicinemedicineHypersensitivityImmunology and AllergyHumansAllergen immunotherapyAsthmaSecondary preventionSublingual ImmunotherapyPrimary preventionbusiness.industrySecondary preventionAtopic dermatitismedicine.diseaseDermatologySlit030104 developmental biology030228 respiratory systembusinessCurrent allergy and asthma reports
researchProduct

The future outlook on allergen immunotherapy in children: 2018 and beyond

2018

Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT …

AllergyAllergen immunotherapymedicine.medical_specialtyAllergen-specific immunotherapy; Allergic rhinitis; Allergy; Children; Food allergy; IgE-mediated allergic diseases; Oral immunotherapy; Prevention; Sub-cutaneous immunotherapy; Sub-lingual immunotherapy; Child; Desensitization Immunologic; Food Hypersensitivity; Humans; Immunoglobulin E; Pediatrics Perinatology and Child HealthAllergySub-cutaneous immunotherapy610 Medicine & healthDiseaseReviewOral immunotherapyIgE-mediated allergic diseasesAllergic rhinitis03 medical and health sciences0302 clinical medicineQuality of life (healthcare)10183 Swiss Institute of Allergy and Asthma ResearchFood allergyFood allergyAllergic rhinitimedicineHumans2735 Pediatrics Perinatology and Child Health030212 general & internal medicineIntensive care medicineChildChildrenAsthmabusiness.industryPreventionlcsh:RJ1-570lcsh:PediatricsAtopic dermatitisImmunoglobulin Emedicine.diseaseSettore MED/38Allergen-specific immunotherapyRegimen030228 respiratory systemDesensitization ImmunologicIgE-mediated allergic diseasebusinessSub-lingual immunotherapyFood HypersensitivityItalian Journal of Pediatrics
researchProduct

The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective.

2020

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the…

AllergyAllergen immunotherapymedicine.medical_specialtybusiness.industryHealth technologymedicine.diseaseRhinitis AllergicAsthmaTelemedicinelaw.inventionClinical trialRandomized controlled triallawDesensitization ImmunologicmedicineImmunology and AllergyHumansIntensive care medicinebusinessmHealthPatient stratificationAsthmaThe journal of allergy and clinical immunology. In practice
researchProduct

Do Tr1 cells play a role in immunotherapy?

1999

AllergyVenomsmedicine.medical_treatmentImmunologyImmune regulationGeneral MedicineImmunotherapyBiologyAllergensTh1 Cellsmedicine.diseaseInterleukin 10CytokineImmune systemTh2 CellsDesensitization ImmunologicInsect venom allergyImmunologymedicineHypersensitivityImmunology and AllergyHumansInternational archives of allergy and immunology
researchProduct

A Hybrid Expressing Genetically Engineered Major Allergens of the <i>Parietaria</i> Pollen as a Tool for Specific Allergy Vaccination

2006

<i>Background:</i> Allergy is an immunological disorder affecting about 25% of the population living in the industrialized countries. Specific immunotherapy is the only treatment with a long-lasting relief of allergic symptoms and able to reduce the risk of developing new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis. <i>Methods:</i> By means of DNA recombinant technology, we were able to design a head to tail dimer expressing disulphide bond variants of the major allergen of the <i>Parietaria </i>pollen. IgE binding activity was studied by Western blot, ELISA inhibition assays and the …

Allergyeducation.field_of_studyParietariabiologyGenetically engineeredImmunologyPopulationSpecific immunotherapyGeneral Medicinebiology.organism_classificationmedicine.disease_causemedicine.diseaseVaccinationAllergenPollenImmunologymedicineImmunology and AllergyeducationInternational Archives of Allergy and Immunology
researchProduct

Allogeneic stem cell transplantation for renal cell carcinoma

2011

Allogeneic hematopoietic stem cell transplantation from a compatible donor has been utilized as adoptive immunotherapy in metastatic, cytokine-refractory renal cell carcinoma (RCC). Since the year 2000, several investigators have established that RCC is susceptible to a graft-versus-tumor effect: they reported that patients with renal cancer may have partial or complete disease responses, in the 20-40% range, after allogeneic transplantation following a reduced-intensity regimen. However, transplant-related mortality is still high in the 10-20% range, and responses are rarely durable. Experimental evidence suggests that donor-derived T cells and natural killer cells are the main mediators o…

Allogeneic transplantationT-Lymphocytesmedicine.medical_treatmentAntineoplastic AgentsHematopoietic stem cell transplantationurologic and male genital diseasesMinor histocompatibility antigenHumansTransplantation HomologousMedicineCytotoxic T cellPharmacology (medical)Molecular Targeted TherapyNeoplasm MetastasisCarcinoma Renal Cellbusiness.industryHematopoietic Stem Cell TransplantationImmunotherapyCombined Modality TherapyKidney NeoplasmsTissue DonorsKiller Cells NaturalTransplantationOncologyImmunologyStem cellbusinessCD8Expert Review of Anticancer Therapy
researchProduct

Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Aminobisphosphonate Gamma delta T cells cancermedicine.medical_treatmentT cellClinical BiochemistryReceptors Antigen T-CellAntineoplastic AgentsModels BiologicalInterleukin 21Immune systemAntigenT-Lymphocyte SubsetsIn vivoNeoplasmsDrug DiscoveryAnimalsHumansCytotoxic T cellMedicinePharmacologyClinical Trials as TopicDiphosphonatesbusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaImmunotherapyKiller Cells Naturalmedicine.anatomical_structureImmune SystemImmunologyInterleukin-2ImmunotherapybusinessImmunologic MemoryExpert Opinion on Biological Therapy
researchProduct

Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays

2015

Abstract The systematic assessment of the human immune system bears huge potential to guide rational development of novel immunotherapies and clinical decision making. Multiple assays to monitor the quantity, phenotype, and function of Ag-specific T cells are commonly used to unravel patients’ immune signatures in various disease settings and during therapeutic interventions. When compared with tests measuring soluble analytes, cellular immune assays have a higher variation, which is a major technical factor limiting their broad adoption in clinical immunology. The key solution may arise from continuous control of assay performance using TCR-engineered reference samples. We developed a simp…

AnalyteT-LymphocytesT cellImmunologyReceptors Antigen T-CellGene ExpressionT-Cell Antigen Receptor SpecificityComputational biologyImmunologic TestsBiologyImmune systemClinical decision makingHLA AntigensmedicineHumansImmunology and AllergyT-cell receptorLimitingmedicine.anatomical_structureImmunologyImmunotherapyProtein MultimerizationSources of errorGenetic EngineeringPeptidesFunction (biology)The Journal of Immunology
researchProduct

Coagulation signaling and cancer immunotherapy.

2019

The last decades have delineated many interactions of the hemostatic system with cancer cells that are pivotal for cancer-associated thrombosis, angiogenesis and metastasis. Expanding evidence shows that platelets, the tissue factor pathway, and proteolytic signaling involving protease-activated receptors (PARs) are also central players in innate and adaptive immunity. Recent studies in immune-competent mice have uncovered new immune-evasive roles of coagulation signaling networks in the development and growth of different preclinical tumor models. Tumor-type specific PAR1 signaling facilitates the escape from immune surveillance by cytotoxic T cells. In addition, tumor-associated macrophag…

Angiogenesismedicine.medical_treatmentReceptors Proteinase-ActivatedMacrophage polarization030204 cardiovascular system & hematology03 medical and health sciencesMice0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsBlood CoagulationTumor microenvironmentInnate immune systembusiness.industryHematologyAcquired immune systemTumor antigen030220 oncology & carcinogenesisFactor XaCancer researchImmunotherapySignal transductionbusinessSignal TransductionThrombosis research
researchProduct